Since pharmacokinetics is an essential factor for natural products, especially for the compound targeting CNS, these findings emphasize the necessity of further studies on designing and improving the bioavailability of natural product-based Hsp90 inhibitors with optimal efficacy in both GBM and neurodegeneration. This evidence concerns the gene HSP90AB1 and glioblastoma.